Therapeutic and Side Effects of Epirubicin on Transmissible Venereal Tumor in Dogs

• Main Authors: Liu Yung-Lin, 劉勇麟
• Other Authors: Chang Ching-Dong
• Format: Others
• Language: zh-TW
• Published: 2005
• Online Access: http://ndltd.ncl.edu.tw/handle/94700841541699097155

碩士 === 國立屏東科技大學 === 獸醫學系 === 93 === In order to investigate the efficacy and side effect of Epirubicin on canine transmissible venereal tumor ( CTVT ), 18 dogs were divided into 3 groups. Group A, 6 healthy dogs were intravenously treated by Epirubicin 30 mg/m2 twice with an interval of 21 days. Group B, negative control, 6 healthy dogs were intravenously treated by normal saline twice with an interval of 21 days. Group C, 6 dogs with CTVT were intravenously treated by Epirubicin 30 mg/m2 twice with an interval of 21 days. The results shown that no significant differences of serum chemistry, serum electrolytes and electrocardiogram were found among groups. However, leukopenia and thrombocytopenia were noticed 7 days after treatment of Epirubicin 30 mg/m2 in Group A and C. Cytologic examination of 6 dogs in Group C revealed that degeneration, pyknosis, karyorrhexis, decreased cell numbers of CTVT were observed and lymphocytes were gradually infiltrated in CTVT. Cell numbers of CTVT were decreased with degeneration and necrosis by histopathological examination. Nuclear pleomorphism, bizarre nuclei, loss of nucleoli, lymphocytic infiltration, increased fibrous connective tissues and blood vessels were observed in CTVT. The result of this study shown that Epirubicin 30 mg/m2 can be intravenously given twice with an interval of 21 days to treat CTVT. After 7 weeks of treatment, CTVT were completely resolved. The side effects of gastrointestinal tracts of vomition and diarrhea and bone marrow depression of mild to moderate leukopenia and thrombocytopenia could be recovered with care to avoid infection. In conclusion, Epirubicin can be used to treat CTVT safely with weekly monitoring by blood examination.. Keywords：Canine, Transmissible venereal tumor, Epirubicin.